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Abstract
This overview of progress made in preventing post‐traumatic osteoarthritis (PTOA) was
delivered in a workshop at the Orthopaedics Research Society Annual Conference in
2019. As joint trauma is a major risk factor for OA, defining the molecular changes within
the joint at the time of injury may enable the targeting of biological processes to prevent
later disease. Animal models have been used to test therapeutic targets to prevent
PTOA. A review of drug treatments for PTOA in rodents and rabbits between 2016 and
2018 revealed 11 systemic interventions, 5 repeated intra‐articular or topical interven-
tions, and 5 short‐term intra‐articular interventions, which reduced total Osteoarthritis
Research Society International scores by 30%–50%, 20%–70%, and 0%–40%, respec-
tively. Standardized study design, reporting of effect size, and quality metrics, alongside a
“whole joint” approach to assessing efficacy, would improve the translation of promising
new drugs. A roadblock to translating preclinical discoveries has been the lack of
guidelines on the design and conduct of human trials to prevent PTOA. An international
workshop addressing this in 2016 considered inclusion criteria and study design, and
advocated the use of experimental medicine studies to triage candidate treatments and
the development of early biological and imaging biomarkers. Human trials for the pre-
vention of PTOA have tested anakinra after anterior cruciate ligament rupture and
dexamethasone after radiocarpal injury. PTOA offers a unique opportunity for defining
early mechanisms of OA to target therapeutically. Progress in trial design and high‐
quality preclinical research, and allegiance with patients, regulatory bodies, and the
pharmaceutical industry, will advance this field.
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1 | INTRODUCTION
This report represents an overview of progress made in understanding
and preventing post‐traumatic osteoarthritis, first delivered in a
workshop with the same title at the Orthopaedics Research Society
Annual Conference in Austin, Texas, in 2019. Overviews of the etiology
of post‐traumatic osteoarthritis, considerations on the design, and
conduct of trials after knee trauma, and potential drug targets revealed
by preclinical studies were presented, as well as recent progress on
clinical trials. Opportunities and challenges in this area were discussed.
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2 | THE ETIOLOGY, EPIDEMIOLOGY, AND
PATHOGENESIS OF POSTTRAUMATIC OA
Osteoarthritis (OA) is a highly prevalent disease and an increasing bur-
den to public health worldwide. Aging and obesity are established risk
factors for OA, but joint trauma is another major contributor to the
disease. For example, observational studies link knee injury in young
adults to a four to sevenfold increased risk for knee OA by middle age.1–5
The resulting phenotype of OA following such known joint injury is often
referred to as post‐traumatic OA (PTOA), that is, assuming that the OA is
caused by joint trauma. Typical knee injuries that increase the risk of
knee OA include intra‐articular ligament rupture, such as anterior
cruciate ligament (ACL) rupture, an acute meniscal tear in the young and
intra‐articular fractures; the most frequent clinically significant injuries
are thought to be in the ACL, the menisci, and/or the hyaline cartilage.6
Epidemiological studies estimate the prevalence of major acute knee
trauma at 77/10,000 persons per year.7 ACL tears have an incidence of
8/10,000 persons per year8,9 and are associated with early subchondral
bone changes after injury.10,11 Thus, there is a potential to observe the
onset of PTOA relatively rapidly after trauma in injured patients, offering
a unique opportunity to study early disease mechanisms, with the aim of
slowing or even halting the cascade of molecular events that occur during
its early development.12,13
Whether the resulting PTOA phenotype is similar or different from
nontraumatic OA remains controversial, but the ability to relate OA
development temporally to a risk event is certainly unique to PTOA. It
is also important to remember that, even without joint injury, some of
these individuals would have developed OA anyway and also that micro
injury‐related pathways may also be relevant in those with other OA,
for example, cases associated with malalignment or obesity. Thus, the
distinction between the classification of PTOA and “primary OA” is far
from clear. In such individuals, one hypothesis is that a joint injury may
accelerate the pathogenesis or just move it earlier as compared with
someone with no joint injury exposure.
In trying to understand the etiology of PTOA, one could classify
the consequences of joint injury into two main heavily inter‐related
pathogenic processes: (1) potentially adverse acute and chronic ef-
fects on molecular homeostasis, for example, inflammatory pathway
activation within joint tissues by acute tissue injury (contusion or
tears), chronic instability (abnormal joint loading), and/or the acute
and chronic molecular effects of intra‐articular bleeding (hemar-
throsis) and (2) acute and chronic consequences of unfavorably al-
tered biomechanical loading patterns and instability due to joint
structural damage and associated muscle weakness. Although we
know from preclinical models that many of the critical molecular
pathways are mechanosensitive, we still know very little about the
relative contribution of these inflammatory and biomechanical
pathways in the initiation, resolution, or progression of human dis-
ease and importantly, about any interactions between the two in the
etiology and pathogenesis of PTOA. Such knowledge is essential be-
cause it is plausible that both these processes may need to be con-
sidered and targeted to reduce the risk of OA following joint injury.
Indeed, restoration of joint stability alone post injury does not
appear to reduce the risk of future OA,14,15 implying that a deeper
and multidisciplinary understanding of disease mechanisms is needed
for progress in this area. It is tempting to speculate that one might
define the pathogenic molecular response within the joint tissues at
the time of the injury, including those inflammatory signaling path-
ways associated with joint pain, dysfunction, and later structural
change, and the relevant biomechanical adverse factors (or those
which bring about repair). This would then enable the targeting of
key biological processes in this early window after the joint injury to
ameliorate later disease.
3 | THERAPEUTIC TARGETS AND
PRECLINICAL MODELS
Various animal models of mechanically induced OA have been used
in preclinical research to identify molecules that could be ther-
apeutically targeted to prevent PTOA. Although OA models vary
considerably across species (mouse, rat, rabbit, dog, sheep, and
horse) and induction method (spontaneous, injury, and surgical), the
vast majority of research testing potential therapeutic compounds
has focused on surgical models in rodents.16 These models destabi-
lize the joint by transection or destabilization of the medial meniscus
(DMM), or anterior cruciate ligament transection (ACLT). Since sur-
gical trauma itself contributes to joint degeneration, noninvasive
models have been developed to determine whether interventions
tested at or close to the time of joint injury could prevent the onset
of PTOA. These models use an external loading device to cause ACL
rupture (ACLr),17,18 focal chondral defects,19 or osteochondral
fracture.20 The advantages of such models in understanding the
natural progression of PTOA as well as revealing potential ther-
apeutic targets have been reviewed.17 However, surprisingly few
preclinical studies have tested whether agents given acutely at the
time of joint injury prevent subsequent OA progression, even though
this would mimic the clinical scenario. The efficacy of drugs used in
such studies are often difficult to compare as they use different
preclinical models of PTOA, are administered at different times after
injury, and use different methods/outcomes to report efficacy.
Guidelines on conduct and reporting of experiments using rodent
models of OA have been published (design and execution of proto-
cols for animal research and treatment [DEPART], animals in re-
search: reporting in vivo experiment [ARRIVE]21) and include
randomization, blinding to treatment, and reporting of effect sizes
with confidence intervals using a validated scoring system such as
the Osteoarthritis Research Society International (OARSI) histolo-
gical scores.22
To reveal new potential treatment opportunities for PTOA, a
literature review by PubMed search was performed between Jan-
uary 1, 2016 and December 31, 2018 for all articles where new
therapies for PTOA were tested in small animals (search terms only
rodent/rat/mouse/rabbit; only PTOA; only drug treatments; exclude
non‐English, Table S1). Results were categorized into whether drugs
were given systemically (orally or by intravenous, subcutaneous, or
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intraperitoneal [i.p.] injection), or locally (intra‐articular [i.a.] injection
or topical), the duration of drug treatment and its temporal re-
lationship to the injury/OA. Since OA is a disease of the entire joint
accompanied by synovitis and bone changes, as well as articular
cartilage loss, and early inflammatory and bone changes appear to be
important in driving PTOA,18 comparisons were made between the
effect size of each intervention on bone and cartilage degeneration,
synovitis, bone changes, and pain (Tables 1 and 2).
This search revealed 18 unique articles reporting the testing of
new treatments. Eleven different systemic interventions were re-
ported (8 given orally and 3 by i.p. injection, and 1 not stated;
Table 1), all but one in surgical models of PTOA, with administration
starting before induction of OA (4) at the time of surgery/injury (7),
or after OA was established (1). Systemic treatment showed
30%–50% reduction in total OARSI scores and 50%–70% reduction
in medial OARSI scores, although the variability in species (rat,
mouse, and rabbit), surgery (DMM and ACLT), intervention start
(from 4 weeks before surgery to 4 weeks after surgery), intervention
duration (4–16 weeks), and study endpoint after injury (2–8 weeks),
plus a lack of consistent reporting of effect size on OARSI score, or
the use of alternative scores such as the Modified Mannkin score,
make efficacy comparisons very difficult. All but two studies re-
ported OARSI score, with various effects on bone reported in eight
studies, pain outcomes reported in two studies, and synovitis con-
sidered in four studies.
Five articles reported the effects of long‐term, local interven-
tions delivered to the joint by i.a. or topical treatments, and all of
these were in rodent surgical models (Table 2). All treatments were
compared with vehicles administered in the same manner. Topical
curcumin nanoparticles were applied daily over 8 weeks from in-
duction of OA and reduced medial OARSI score by 27%, OARSI
synovitis score by 33%, and reduced bone score and pain. Kartogenin
i.a. injections were given weekly, and FGF‐9, FGF‐18, and 5Z7 i.a.
injections were given bi‐weekly, at the induction of OA, or 1 or 2
weeks later, for 4–12 weeks. Based on our interpretation of the
graphical data where effect sizes were not reported, OARSI severity
scores were reduced by 20%–70% (total) or 30%–70% (medial) after
repeated i.a. treatments (Table 2). The impact of repeated i.a. injec-
tions on other outcomes is difficult to assess as synovitis was only
considered in the one of these i.a. studies, and pain not at all.
The final five studies assessed short‐term i.a. interventions, de-
livered one to three times. Four of these studies were in surgical
models (rabbit/rat/mouse ACLT), with one in mouse ACLr. Hyalur-
onan (HA)‐binding peptide and micronized porcine urinary bladder
reduced medial OARSI score by 30%–50%, but since the interven-
tions were not given until Day 14 (when OA is already established in
the mouse ACLT model), these experiments assess their effect on
“fast progressing OA” rather than prevention of PTOA. The two
studies where treatments were given i.a. at the time of surgery/injury
(scaffold and blood in rat ACLT, and HADD‐4G/PRP/HADD‐4G+PRP
in mouse ACLr) were ineffective at preventing degeneration. The
final study showed that a single i.a. injection of Avidin‐
dexamethasone 7 days after surgery in rabbit ACLT reduced OARSI
score by 40% and also reduced synovitis and bone score, although
effects on pain were not reported.
Despite the major opportunities offered by intervention in
PTOA, only three of the preclinical studies reported in 2016–2018
recapitulated the most likely clinical scenario, where a preventative
treatment would be administered over a short time at or around the
time of acute injury. All but one of these studies was in surgical
models of PTOA, where the inflammatory and degenerative effects
of sham surgery complicate the interpretation of any protective ef-
fects of treatment. Four recent studies published after the sys-
tematic PubMed search (Table 3, 2019–2020) exclusively use
nonsurgical trauma models where treatment is given at the time of
injury either orally (Doxycycline23 or GKT13783124) or as i.a. injec-
tion (dexamethasone,25 2,3‐Dioxo‐6‐nitro‐1,2,3,4‐tetrahydrobenzo[f]
quinoxaline‐7‐sulfonamide [NBQX]26). Oral doxycycline reduced
OARSI score by 30%, improved synovitis by 30%–40% and improved
weight‐bearing.23 GKT137831 (Nox4 inhibitor) significantly reduced
early bone changes detected by microCT after ACLr.24 Single i.v. or
i.a. injection of dexamethasone did not affect OARSI or bone scores.
Two i.a. injections of the glutamate receptor antagonist (RA) NBQX
reduced OARSI scores by 50% and bone scores by 75% after ACLr
but did not affect end‐stage inflammation score or pain.26
In summary, these preclinical reports identify promising new ther-
apeutic targets, but comparisons between targets are hampered by
variations in reporting and types of outcome measures collected. Re-
ference to ARRIVE guidelines, randomization of treatments, and blinding
of investigators to treatments were limited to two studies, whereas eight
of the papers do not mention any of these important quality require-
ments (Tables 1–3). Seven papers considered the effects of treatment in
cartilage, bone, and synovium, and only two papers combined this mul-
titissue analysis with indicators of pain (Tables 1–3). Compliance with
reporting guidelines and a more holistic approach to the analysis of the
effects of interventions is necessary to improve the effective translation
of preclinical discovery.
4 | WHY INTERVENE AT THE TIME OF
KNEE INJURY?
PTOA represents a significant clinical burden in its own right (c. 12% of
all OA cases) but arguably also an unrivaled opportunity for intervention.
Unlike more “usual” (nontraumatic) OA where onset is often difficult to
define and structural abnormalities often predate symptoms by years,27
the timing of the joint injury and therefore the initiation of processes in
PTOA is known. This means that we can exploit this knowledge in var-
ious ways for clinical benefit: to gain a better understanding of the in-
itiating molecular processes and disease pathogenesis, to define
prognostic biomarkers, and to identify new therapeutic targets for the
disease. In practical terms, as around 50% of individuals develop PTOA
after a significant injury,3 meaningful clinical treatment may benefit from
stratification of those at the time of the injury who appear to be at the
highest risk of PTOA, focusing early interventions in these individuals to
prevent future OA.
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5 | PROGRESS IN INTERNATIONAL
CONSENSUS ON THE DESIGN AND
CONDUCT OF INTERVENTIONAL TRIALS
AFTER KNEE TRAUMA
Current interventions at the time of acute knee injury, including
rehabilitation and surgical interventions, such as ligament re-
construction, aim to improve knee pain and instability, and restore
function as rapidly as possible. There has been much controversy
about the relative benefits and risks of different types and timings of
interventions in the posttraumatic period, particularly surgical, and
whether certain surgical approaches could in some circumstances
exacerbate an injury response or delay recovery.46–48 Physiotherapy
approaches have been reported49 and exercise intervention trials
started (NCT04363476). However, to date, there is a lack of high‐
quality evidence for the efficacy of any existing interventions that
follow the injury reducing an individual's risk of later PTOA.
There is also a lack of guidance or internationally agreed ap-
proach on the design and conduct of interventional trials at the time
of knee trauma, which seek to prevent PTOA, representing an unmet
need. Guidance would need to be appropriate for various different
types of interventions, which potentially seek to target different
mechanisms, and which might be used either alone or in combination.
As well as exercise/rehabilitation and surgical interventions, these
could include pharmacological, cellular or biological approaches, or
devices and orthotics.
Several current barriers to interventional studies exist in this
area. Probably, the biggest is that there is no Food and Drug Ad-
ministration label for “prevention of (PT)OA”. There are few pre-
cedents in this area, particularly for clinical trials of investigational
medicinal products (CTIMPs) and a lack of academic or pharma
funding or activity because of this. Uncertainties span many aspects
of trial design: the study population to be included, the timing of
intervention, and its appropriate comparator and the use of out-
comes, which are both sensitive, reproducible, and feasible.
The lack of guidelines and consensus in this area was identified
as a roadblock for those working in clinical translation in PTOA. In
collaboration with Versus Arthritis (then Arthritis Research UK, the
U.K.'s largest musculoskeletal research charity), an international
workshop was convened in London, UK, in November 2016 to out-
line considerations and research needs around the design and con-
duct of interventional studies at the time of knee injury. The 32
stakeholders present included clinicians (orthopedic surgeons,
rheumatologists, sports and exercise physicians, physiotherapists),
pharmaceutical industry representatives, patient representatives,
discovery and preclinical scientists, bioengineers, and clinical
triallists.
Considerations were to be relevant to all forms of interventional
study but not quasi‐controlled studies or cohorts. On the day, a
systematic literature review and summaries of key areas from
leading experts in the field were presented. Workshops and then an
iterative process developed considerations in four main areas: elig-
ibility, outcomes (including biomarkers), the definition of injury and
timing of intervention, comparator, and multimodality interventions.
Knowledge gaps and research needs were also outlined. The output
of this exercise is reviewed here; the detailed report has now been
published.50
The literature review considered all published interventional
randomized controlled trials (RCTs) or non‐RCT trials. Thirty‐seven
articles were identified, which included mainly surgical studies of
ACLR, patellar dislocation, tibial fracture, and a minority of other
injury types. The studies were generally of small size (median
category 20–50 participants), of long duration (11 studies of over
5 years), with only a minority of studies stating a priori power calcu-
lations and primary outcome. Just 2 of the 37 were classical CTIMPs.
5.1 | Summary of considerations
The application of existing published international guidelines on the
conduct of trials in OA was encouraged where possible51–53 and also
the use of existing design and international reporting guidelines such
as CONSORT and STROBE.54,55 Key (or more controversial) points
are included below.
5.2 | Study populations
It was felt important to include patients in studies who had a de-
finable structural acute injury and represented common groups with
a modifiable process. An example of this was ACL injury with an
associated acute meniscal tear. There was an awareness that the
inclusion of extreme phenotypes, perhaps those with “in-
evitable” disease should be avoided, as well as those likely to have
degenerative meniscal tear/established OA, as they would confound
the outcome. A discussion around an upper age threshold to exclude
cases more likely to have OA proposed, including only those age 35
or younger initially in such studies. Since some injuries have a lower
risk of future OA than others, stratification was desirable to avoid
overtreatment. Ideally, those at the highest risk of OA should be
identified, although predictive biomarkers or other algorithms for
doing so are currently lacking.
5.3 | Timing of the intervention
An appropriate “window of opportunity” for any given intervention
should be defined. This needs to be specific not only to the target,
the route, and nature of the treatment but also acceptable and
feasible for patients and clinicians. At an early stage of development,
smaller experimental medicine studies (with molecular rather than
patient‐reported outcomes), or feasibility studies of agents should be
considered to answer such questions. These should refine and enable
study design, and help to triage more robustly likely new targets
ahead of larger, more costly “classical” clinical trials. At a more
general level, such studies will grow and establish confidence in
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optimal study design for any given target. Patients should also be
involved at an early stage in the design of studies.
5.4 | Comparator
Interventional studies should always use a carefully designed com-
parator, placebo, or sham. Surgical placebo was noted as both sup-
ported and possible in this area.56,57 Although multimodality
interventions were commonplace in clinical practice, it was felt es-
sential to test and understand the individual effects of interventions
before testing multimodality interventions, which was acknowledged
as challenging.
5.5 | Outcome measures
One of the known challenges in this area and also in OA as a whole is
that “traditional“ outcomes such as X‐rays are insensitive to change,
necessitating large numbers of participants in long studies, which are
expensive and unfeasible. There is a need to identify earlier “surro-
gate” endpoints. To this end, interventional studies and cohort stu-
dies should be encouraged to include multiple early measures
(biomarkers, alternative imaging outcomes, patient‐reported out-
come measures [PROMs]) to build knowledge. Assumptions about
the relationships and relevance of, for example, PROMs and struc-
tural outcomes should be avoided, but rather evidence sought,
aiming for sensitive, specific measures of any form, which shorten
studies.There should be close liaison with industry and regulators
about what is acceptable to them.
5.6 | Translational studies
While the potential for biomarker stratification and for early mole-
cular or imaging‐based surrogates of longer‐term outcomes in stu-
dies was identified, there are none currently with sufficient evidence
to support their use. Studies that incorporate longitudinal bio‐sample
collection (synovial fluid, plasma, serum, DNA, RNA, and tissue) and
magnetic resonance imaging (MRI), X‐ray, or other experimental
imaging were encouraged.
High‐quality cohort studies may provide us with a greater un-
derstanding of processes and potential novel prognostic markers of
outcomes. Two studies identifying associations between synovial
fluid markers and outcomes were given. Amano et al. conducted a
small study of 26 participants undergoing ACL reconstruction, ex-
amining a number of inflammatory response proteins in the synovial
fluid at this time. The outcome was T1ρ and T2 values on cartilage
MRI, where a higher score correlated with abnormal cartilage in-
tegrity. Of note, a “high GAG cluster” was identified (which was as-
sociated with lower interleukin (IL)‐6, tumor necrosis factor‐α, and
matrix metalloproteinase 3 than the “inflammation cluster”), which
was associated with higher T1ρ/T2 in medial tibial/patellar cartilage.
In another longitudinal cohort study, the knee injury cohort at the
Kennedy study, 150 individuals with a variety of clinically significant
acute knee injuries were followed over time. Baseline synovial fluid
biomarkers were shown to be associated with patient‐reported
symptoms at the time of injury and also with early clinical out-
comes.13 The markers tested had been selected from a surgically
induced mouse model of PTOA. Appropriate use of preclinical animal
models represents an opportunity to improve translation in this area.
6 | CLINICAL TRIALS
The only published human trials for the prevention of PTOA to date
in man have focused on anti‐inflammatory treatments: primarily
dexamethasone and anakinra, and IL‐1 RA. The first was a proof of
concept RCT using i.a. anakinra in just 11 subjects58 (NCT00332254).
The second RCT was in adolescent/pediatric cases with an ACL
injury, with short‐term patient‐reported outcomes and biomarkers
collected after i.a. dexamethasone or placebo.59 The evidence re-
view to identify interventional studies with specific reference to
PTOA of the knee50 identified a deficiency in this area with only
five pharmacologic trials of any nature for treating ACL rupture
(MSCs + HA vs. HA; IL‐1RA vs. saline; IL‐1 inhibitor vs. placebo,
femoral nerve block + ACL reconstruction vs. ACL reconstruction;
oral glucosamine for acute knee injury).
There has been recent concern that several biologically active
or cellular therapies are gaining credence for use at the time of
knee injury and for other indications without sufficient testing in
an RCT setting or formal licensing, with the hope that they may
prevent OA. Minimum reporting standards for therapies, such as
stem cells and platelet rich plasma (PRP), have since been
published.
Anakinra (IL‐1RA) has progressed to Phase 1/2 trials for the
prevention of injury‐induced OA after ACL rupture (ClinicalTrials.
gov: NCT02930122, NCT03968913), whereas dexamethasone
(ClinicalTrials.gov: NCT02318433) has completed a Phase 1 trial for
this indication in radiocarpal injury (data not yet published).
The evidence from animals to support these targets is of inter-
est. IL‐1RA given as a single i.a. injection reduced degeneration and
inflammation after mouse tibial fracture,60,61 and this effect was
enhanced using sustained i.a. release.62,63 However, a recent sys-
tematic review on the use of corticosteroids in vivo at the time of
injury64 revealed that methylprednisolone appeared to be degen-
erative in an equine exercise model, while it was protective in a
canine model where the ACL was sectioned. In healthy rabbits,
prednisolone acetate was found to be detrimental, while after sur-
gical drill injury, dexamethasone (i.a. 0.5 mg/kg) was protective if
given every 3 days for 3 weeks65 or at the time of drill injury66 but
was not protective when given 7 days post‐ACLT.40 Recent reports
show that Avidin‐dexamethasone 7 days after surgery in rabbit ACLT
reduced OARSI score by 40%, and also reduced synovitis and bone
score,40 but that dexamethasone was ineffective in a mouse tibial
compression model.25
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7 | CHALLENGES AND OPPORTUNITIES
7.1 | Translation
This review highlights some promising potential therapies for the
prevention of PTOA, but also some challenges while interpreting the
literature. All but one of the reported studies on PTOA between
2016 and 2018 were performed in surgical models of OA, with dif-
ferent intervention times, routes of administration, and start and
endpoints. There is a need to ensure that the animal model and
intervention regime matches the potential clinical application. The
majority of studies did not clearly state effect sizes and did not
measure all clinically relevant outcomes (degeneration, synovitis,
bone score, and pain). More recently, nonsurgical PTOA models offer
new opportunities to delineate the relationship between in-
flammatory and mechanical drivers of pathology. However, the use
of such noninvasive models in testing the efficacy of interventions to
prevent PTOA has been limited.
To translate this preclinical work effectively, it is essential that
the methods for assessing the efficacy of each drug are consistent
and that the way in which the drug is tested is applicable to the
ultimate clinical application. As noted by others, universal adoption
of experimental design and execution (DEPART) and reporting
(ARRIVE) guidelines are needed to ensure that study quality is high,
design aspects transparent, and bias is not unwittingly introduced.
The reporting of power calculations, effect sizes, and confidence
intervals using standard scoring systems and the preregistration of
all preclinical studies to facilitate the reporting of negative results
would accelerate the prioritization of new potential therapies for the
prevention of PTOA.
7.2 | Clinical
The knee‐injury “model” of OA in humans is a highly attractive model
for PTOA research: acute knee trauma is common and relevant injuries
well‐defined and the onset of PTOA of the knee is relatively rapid. The
extent of injury necessary to “cause” OA and the relative importance of
different types of injury could be better understood. There are accepted
imaging protocols and scoring systems for MRI of this joint in the
context of injury and knee X‐ray outcomes (albeit with its limitations,
discussed elsewhere). The synovial fluid analysis provides a window on
the joint at this time and is relatively straight forward in large joints
such as the knee. Assessment of the presence of hemarthrosis is also
possible via this invasive monitoring, which may represent an important
prognostic factor at the time of joint injury.67 Following those at the
time of knee injury thus offers a unique opportunity to prevent joint
degeneration by measuring and modulating molecular and structural
events arising from the trauma.12,13
However, there are also important hurdles in the field of PTOA
research of the knee. These include challenges in designing long-
itudinal cohort studies and clinical trials given the large hetero-
geneity of patients with knee injuries and the current long follow‐up
time needed for observing OA development (even if PTOA may
develop more rapidly than other forms of OA). In addition, following
the earliest disease processes has traditionally involved expensive,
time‐consuming imaging methods, such as MRI, which limits feasi-
bility. There are also further challenges in monitoring and char-
acterizing the often subtle changes in the joint over time and in
interpreting which changes may be part of the disease process as
opposed to what may be considered “normal response to injury” or
“normal aging” of the joint, that is, not necessarily related to symp-
toms or disease.68 Furthermore, it may be hard to determine whe-
ther disease‐related changes in the posttraumatic joint are in fact
attributable to the injury, especially in the presence of other OA risk
factors in an individual. Having sufficient numbers to allow the
consideration of all other relevant clinical and demographic factors in
individual outcomes in analyses is essential.
8 | CONCLUSIONS
In contrast to many other risk factors for OA, such as age, obesity,
and genetic factors, the risk posed by joint trauma is relatively well‐
defined and usually easy to pinpoint in time, offering a unique op-
portunity for understanding the early mechanisms of OA. The first
considerations for interventional trials in this area were published in
201950 and provide much‐needed foundations for work on future
guidelines to progress this field. The key to achieving a breakthrough
in this field is arguably cross‐disciplinary research involving epide-
miologists, orthopedic surgeons, biomechanical experts, molecular
scientists, rheumatologists, physiotherapists, pharmacologists, radi-
ologists, and other medical imaging experts, to achieve a compre-
hensive understanding of the etiology and pathogenesis of PTOA
relevant to a successful translation. It is imperative that we work
closely with patients, regulatory bodies, and the pharmaceutical in-
dustry to reach these goals. Preclinical models in this area should fuel
translational and experimental medicine research in this area. Re-
search testing interventions in models should report effects on all
joint tissues and comply with the highest conduct and reporting
standards. Despite the challenges, there remains a real opportunity:
the prevention of OA at the time of joint trauma, which may bring
about much‐needed traction in the treatment of OA as a whole.
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